“Importantly, the growth we're realizing today and our expanding capacity serve to further reinforce the confidence we have in our long-term 13% to 16% growth objective.”

In context

“eply, and building the foundations to support our growth objectives for years to come. Now I'll turn it back to Andrew. Andrew Witty: Thanks John. Before opening up for questions, I'll offer some preliminary observations about next year, while reserving most of this conversation for our investor conference on November 29th. Our businesses continue to build momentum, while maintaining flexibility and adaptability for an ever-changing landscape, even as we invest for the future. We're focused on our strategic growth pillars and driving efficiencies throughout the enterprise at an accelerated pace. At this distance, analyst earnings estimates for 2024 reasonably reflect the performance view we expect to offer in November, with consensus near the upper end of our likely initial outlook range. Importantly, the growth we're realizing today and our expanding capacity serve to further reinforce the confidence we have in our long-term 13% to 16% growth objective. And with that, I'll now ask the operator to open up for questions. Operator: The floor is now open for questions. [Operator Instructions] We'll go first to Lisa Gill with JPMorgan. Lisa Gill: Good morning, and thanks for the comments. I wanted to start with GLP-1s and really understand from two sides. One, when we think about rates for 2024, can you talk about what you've incorporated in rates around GLP-1s, especially around weight loss as we have new products coming to the market? And how do I think about that from the PBM side when we think about the services that you can wrap around that and sell from a PBM perspective? Andrew Witty: Lisa, thanks so much for the question. In a second, I'll ask Brian Thompson from UHC and Dr. Patrick Conway to respond to your comments in a little more”